Sarepta Therapeutics (SRPT) said Friday that three patients born with a rare muscle-wasting disease called limb-girdle muscular dystrophy showed improvements in strength and function when measured nine months after a one-time infusion of an experimental gene therapy.

The encouraging limb-girdle gene therapy data are a welcome dose of good news for Sarepta, which has seen its problems mount and its stock price fall since the Food and Drug Administration rejected a Duchenne muscular dystrophy drug in August. Sarepta shares were up 6% Friday.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Comments are closed.

Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy